Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies

Open Access
Publisher Website
Google Scholar
Abstract
Background. Based on its success as a transplant immunosuppressor, there is intense interest in using rapamycin in the treatment of progressive glomerulopathies involving native kidneys. However, we call attention to the potential toxicity associated with the use of rapamycin in this setting. Methods. We conducted a study to examine the efficacy and safety of rapamycin in patients with progressive chronic renal failure. Eleven patients with either focal segmental glomerulosclerosis, immunoglobulin A nephropathy, membranous nephropathy or membrano-proliferative glomerulonephritis and progressive renal failure (defined as an increase in >25% of baseline serum creatinine over the last year or loss of glomerular filtration rate ≥5 ml/min/year as determined by the Cockcroft–Gault formula), proteinuria ≥1.0 g/24 h and with a creatinine clearance of ≥20 ml/min/1.73 m2 were entered into a 12 month study. Patients were treated with rapamycin, starting at 5 mg/day, orally, aiming for target blood levels of 7–10 ng/dl. All patients were on treatment with an angiotensin-converting enzyme inhibitor and/or an angiotensin receptor blocker, aiming to control blood pressure ≤145/90 mmHg. Results. Six patients developed acute renal failure, defined as an increase in serum creatinine ≥0.5 mg/dl (baseline: 3.2±0.9 mg/dl; peak: 5.6±1.6 mg/dl; P15 ng/dl. Conclusions. Rapamycin can cause nephrotoxicity in some patients with chronic glomerulopathies. Whether the toxicity is solely related to rapamycin, due to the combination of proteinuria and rapamycin, or other unknown factor use is presently undetermined.